Seattle Genetics (SGEN) volatility flattens of FDA recommendation

Seattle Genetics (Nasdaq: SGEN) is recently down 1.2% following the Oncologic Drugs Advisory Committee to the FDA voting 10-0 to recommend that the FDA grant accelerated approval of Adcetris for the treatment of patients with Hodgkin lymphoma who relapse after autologous stem cell transplant. August put option implied volatility is at 53, December is 58; near its six-month average of 56 according to Track Data.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Uniti Group (UNIT) 3700 contracts of July 13 calls trade, share up 7%
• Boeing (BA) call put ratio 1.9 calls to 1 put as share price up 4.9%
• Lennar Corp. (LEN) call put ratio 1.8 calls to 1 put into quarter results